Expert Interview
Discussing 3SBio's bispecific antibody targeting PD-1 and VEGF, SSGJ-707, as monotherapy in patients with advanced non-small cell lung cancer.
Ticker(s): 1530.XHKG, PFEInstitution: Mount Sinai
- Assistant professor of Medicine, Hematology and Medical Oncology, and a board certified medical oncologist who specializes in the treatment of lung cancer and other thoracic malignancies.
- Translational researcher focused on studying predictive biomarkers and developing novel targeted and immunotherapy trials aimed at improving treatment outcomes in lung cancer patients.
- PI of several lung cancer trials, including investigator initiated trials based on proteogenomic analyses used to identify novel therapeutic targets.
What is your perspective on the rationale for dual targeting of PD-1 and VEGF in a single bispecific antibody like SSGJ-707? Do you see meaningful synergy in modulating both immune activation and angiogenesis simultaneously?
Added By: sara_adminGiven the crowded PD-1 and VEGF therapeutic landscape in NSCLC, what differentiating clinical signals or patient populations would you look for to determine whether SSGJ-707 offers a real therapeutic advantage as monotherapy?
Added By: sara_adminAre there any unique safety or immune-related adverse event concerns you would anticipate with a PD-1/VEGF bispecific, based on mechanism or existing bispecific experience in solid tumors?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
